Alessio Imperiale1,2, Caroline Boursier3, Nicolas Sahakian4, Eric Ouvrard5, Elodie Chevalier3, Frédéric Sebag6, Pietro Addeo7, David Taïeb4,8. 1. Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe, Université de Strasbourg, Strasbourg, France; a.imperiale@icans.eu. 2. Molecular Imaging-DRHIM, IPHC, UMR 7178, CNRS/Unistra, Strasbourg, France. 3. Nuclear Medicine, University Hospital of Nancy, Nancy, France. 4. Nuclear Medicine, La Timone University Hospital, Aix-Marseille University, Marseille, France. 5. Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe, Université de Strasbourg, Strasbourg, France. 6. Endocrine Surgery, Conception University Hospital, Aix-Marseille University, Marseille, France. 7. Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France; and. 8. European Center for Research in Medical Imaging, Aix-Marseille University, Marseille, France.
Abstract
Our objective was to assess the value of 68Ga-DOTATOC and carbidopa-assisted 18F-fluorodihydroxyphenylalanine (18F-DOPA) in 21 hypoglycemic patients. Methods: All patients who underwent 68Ga-DOTATOC or carbidopa-assisted 18F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. Results: During the study period, 21 patients underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. 18F-DOPA and 68Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by 18F-DOPA PET/CT and 3 by 68Ga-DOTATOC PET/CT only. 18F-DOPA and 68Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. Conclusion: When 68Ga-exendin-4 is not available, 68Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.
Our objective was to assess the value of 68Ga-DOTATOC and carbidopa-assisted 18F-fluorodihydroxyphenylalanine (18F-DOPA) in 21 hypoglycemic patients. Methods: All patients who underwent 68Ga-DOTATOC or carbidopa-assisted 18F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. Results: During the study period, 21 patients underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. 18F-DOPA and 68Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by 18F-DOPA PET/CT and 3 by 68Ga-DOTATOC PET/CT only. 18F-DOPA and 68Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. Conclusion: When 68Ga-exendin-4 is not available, 68Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.
Authors: L Tessonnier; F Sebag; C Ghander; C De Micco; R Reynaud; F F Palazzo; B Conte-Devolx; J F Henry; O Mundler; D Taïeb Journal: J Clin Endocrinol Metab Date: 2009-11-13 Impact factor: 5.958